Stealth BioTherapeutics Corp (MITO) - Strategic SWOT Analysis Review

May 2020 | 36 pages | ID: S8855B23F3DEN
GlobalData

Abstracts

Stealth BioTherapeutics Corp (MITO) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Stealth BioTherapeutics Corp (Stealth BioTherapeutics), formerly Stealth Peptides International Inc, a subsidiary of Morningside Venture Investments Ltd, is an early stage biotechnology company. It discovers, develops, and commercializes novel therapies for diseases and disorders associated with mitochondrial dysfunction. The company is investigating elamipretide, a peptide compound that penetrates into cell membranes, for the treatment of primary mitochondrial myopathy, barth syndrome, leber’s hereditary optic neuropathy, and dry age-related macular degeneration. Stealth BioTherapeutics is also evaluating SBT-20 for the treatment of neurodegenerative diseases related to mitochondrial dysfunction; and SBT-272, a pre-clinical candidate, for the treatment of rare neurodegenerative diseases. The company works in partnership with physicians, scientists, and research institutions for advancing therapeutics for the treatment of diseases arising from mitochondrial dysfunction. Stealth BioTherapeutics is headquartered in Newton, Massachusetts, the US.

Stealth BioTherapeutics Corp Key Recent Developments

May 07,2020: Stealth BioTherapeutics reports first quarter 2020 financial results and recent business highlights
Apr 01,2020: Stealth BioTherapeutics reports fiscal year 2019 financial results and recent business highlights
Nov 14,2019: Stealth BioTherapeutics reports third quarter 2019 financial results and recent business highlights
Oct 11,2019: Alexion, Stealth to develop elamipretide for mitochondrial diseases
Sep 03,2019: Stealth BioTherapeutics announces appointment of Robert Weiskopf as Chief Financial Officer

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

Stealth BioTherapeutics Corp - Key Facts
Stealth BioTherapeutics Corp - Key Employees
Stealth BioTherapeutics Corp - Key Employee Biographies
Stealth BioTherapeutics Corp - Major Products and Services
Stealth BioTherapeutics Corp - History
Stealth BioTherapeutics Corp - Company Statement
Stealth BioTherapeutics Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Stealth BioTherapeutics Corp - Business Description
R&D Overview
Stealth BioTherapeutics Corp - Corporate Strategy
Stealth BioTherapeutics Corp - SWOT Analysis
SWOT Analysis - Overview
Stealth BioTherapeutics Corp - Strengths
Stealth BioTherapeutics Corp - Weaknesses
Stealth BioTherapeutics Corp - Opportunities
Stealth BioTherapeutics Corp - Threats
Stealth BioTherapeutics Corp - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Stealth BioTherapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Stealth BioTherapeutics Corp, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Stealth BioTherapeutics Corp, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

May 07, 2020: Stealth BioTherapeutics reports first quarter 2020 financial results and recent business highlights
Apr 01, 2020: Stealth BioTherapeutics reports fiscal year 2019 financial results and recent business highlights
Nov 14, 2019: Stealth BioTherapeutics reports third quarter 2019 financial results and recent business highlights
Oct 11, 2019: Alexion, Stealth to develop elamipretide for mitochondrial diseases
Sep 03, 2019: Stealth BioTherapeutics announces appointment of Robert Weiskopf as Chief Financial Officer
Aug 14, 2019: Stealth BioTherapeutics reports first half 2019 financial results and recent business highlights
May 15, 2019: Stealth BioTherapeutics reports first quarter 2019 financial results
Apr 04, 2019: Stealth Biotherapeutics reports fiscal year 2018 financial results and recent business highlights

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Stealth BioTherapeutics Corp, Key Facts
Stealth BioTherapeutics Corp, Key Employees
Stealth BioTherapeutics Corp, Key Employee Biographies
Stealth BioTherapeutics Corp, Major Products and Services
Stealth BioTherapeutics Corp, History
Stealth BioTherapeutics Corp, Subsidiaries
Stealth BioTherapeutics Corp, Key Competitors
Stealth BioTherapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Stealth BioTherapeutics Corp, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Stealth BioTherapeutics Corp, Recent Deals Summary

List Of Figures

LIST OF FIGURES

Stealth BioTherapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Stealth BioTherapeutics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

Regeneron Pharmaceuticals Inc
NeuroVive Pharmaceutical AB
IVERIC bio Inc
Ionis Pharmaceuticals Inc
Hemera Biosciences Inc
Genzyme Corp
Genentech Inc
BioElectron Technology Corp
Astellas Pharma Inc
Apellis Pharmaceuticals Inc
Allegro Ophthalmics LLC
Alimera Sciences Inc